Sarepta Therapeutics
Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Key Statistics
Stock Snapshot
Sarepta Therapeutics(SRPT) stock is priced at $21.00, giving the company a market capitalization of 2.2B. It carries a P/E multiple of -7.24.
On 2025-11-28, Sarepta Therapeutics(SRPT) stock traded between a low of $19.31 and a high of $21.21. Shares are currently priced at $21.00, which is +8.8% above the low and -1.0% below the high.
Sarepta Therapeutics(SRPT) shares are trading with a volume of 3.25M, against a daily average of 4.33M.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.
SRPT News
Wondering if Sarepta Therapeutics is finally trading at a bargain price? You are not alone, as savvy investors often watch for signs the stock might be underval...
Citi analyst Yigal Nochomovitz maintained a Sell rating on Sarepta Therapeutics yesterday and set a price target of $8.00. TipRanks Black Friday Sale Claim 60%...
Image source: The Motley Fool. Tuesday, Nov. 25, 2025 at 4:30 p.m. ET CALL PARTICIPANTS President and CEO — Christopher Anzalone Chief Medical Officer and Head...
Analyst ratings
56%
of 25 ratingsMore SRPT News
Sarepta (SRPT) Therapeutics announced that the FDA has approved dosing in Cohort 8 of ENDEAVOR. The purpose of Cohort 8 is to evaluate the use of an enhanced im...
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Sarepta Therapeutics. The associated price target remains the same with $20.00. TipRa...
In November 2025, Sarepta Therapeutics announced progress in its Phase 1/2 clinical study of SRP-1003 for myotonic dystrophy, and provided updates to the prescr...